Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 17, 2026MedicineOpen Access

Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports

View Full Paper
Ask AI
Bookmark
Share

Authors

NANasser M. AlorfiUmm al-Qura UniversityMAMansour M. AlourfiSoliman Fakeeh HospitalAAAmmar AlDabbaghSoliman Fakeeh Hospital

Discussion

Loading...

Member takes

Implication

Descriptive analysis of global adverse drug reactions of semaglutide, indicating the need for ongoing monitoring.

Key Points

  • The study aims to analyze the global profile of adverse drug reactions associated with semaglutide.
  • Retrospective descriptive analysis using WHO VigiAccess data
  • Data retrieved on October 18, 2025
  • Summary of ADRs by Medical Dictionary for Regulatory Activities organ class
  • 81,770 ADR reports associated with semaglutide were identified
  • Most common ADRs were gastrointestinal disorders (28%), general disorders (12%), and injuries (11%)
  • Reporting significantly increased from 2018 to 2025, coinciding with increased semaglutide usage

Cite This Study

Alorfi et al. (2026) studied this question.

synapsesocial.com/papers/6a095b8e7880e6d24efe14d5https://doi.org/10.1097/md.0000000000048811
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database2024 · 88 citations
  2. 2GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes2025 · 59 citations
  3. 3Neuroprotective Activity of GLP-1 Analogues: General Understanding of Implementation Mechanisms2024 · 3 citations
  4. 4Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis2025 · 83 citations
  5. 5Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia2024 · 10 citations